JP7102354B2 - ４－（５－（４，７－ジメチルベンゾフラン－２－イル）－１，２，４－オキサジアゾール－３－イル）安息香酸の結晶形態及びそれらの調製方法 - Google Patents

４－（５－（４，７－ジメチルベンゾフラン－２－イル）－１，２，４－オキサジアゾール－３－イル）安息香酸の結晶形態及びそれらの調製方法 Download PDF

Info

Publication number
JP7102354B2
JP7102354B2 JP2018566470A JP2018566470A JP7102354B2 JP 7102354 B2 JP7102354 B2 JP 7102354B2 JP 2018566470 A JP2018566470 A JP 2018566470A JP 2018566470 A JP2018566470 A JP 2018566470A JP 7102354 B2 JP7102354 B2 JP 7102354B2
Authority
JP
Japan
Prior art keywords
bhba
neuropathy
crystal form
treatment
nerve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018566470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019522650A5 (enExample
JP2019522650A (ja
Inventor
マックスウェル ローレンス，ロニー
アレット，エドウィン
デビッド ボースウィック，アラン
テレサ ブラウン，ジェーン
パトリック トーマス コーコラン，ジョナサン
カストロ バスコンセロス ゴンカルベス，マリア ベアトリス デ
バレット カリンジアン，サルキス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Publication of JP2019522650A publication Critical patent/JP2019522650A/ja
Publication of JP2019522650A5 publication Critical patent/JP2019522650A5/ja
Application granted granted Critical
Publication of JP7102354B2 publication Critical patent/JP7102354B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • AIDS & HIV (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2018566470A 2016-06-22 2017-06-16 ４－（５－（４，７－ジメチルベンゾフラン－２－イル）－１，２，４－オキサジアゾール－３－イル）安息香酸の結晶形態及びそれらの調製方法 Active JP7102354B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1610867.2A GB201610867D0 (en) 2016-06-22 2016-06-22 Crystalline forms of a therapeutic compound and processes for their preparation
GB1610867.2 2016-06-22
PCT/EP2017/064802 WO2017220446A1 (en) 2016-06-22 2017-06-16 Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation

Publications (3)

Publication Number Publication Date
JP2019522650A JP2019522650A (ja) 2019-08-15
JP2019522650A5 JP2019522650A5 (enExample) 2020-07-09
JP7102354B2 true JP7102354B2 (ja) 2022-07-19

Family

ID=56895172

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018566470A Active JP7102354B2 (ja) 2016-06-22 2017-06-16 ４－（５－（４，７－ジメチルベンゾフラン－２－イル）－１，２，４－オキサジアゾール－３－イル）安息香酸の結晶形態及びそれらの調製方法

Country Status (10)

Country Link
US (2) US10870644B2 (enExample)
EP (1) EP3475274A1 (enExample)
JP (1) JP7102354B2 (enExample)
CN (1) CN109415356B (enExample)
AU (1) AU2017279865B2 (enExample)
CA (1) CA3025858C (enExample)
GB (1) GB201610867D0 (enExample)
IL (1) IL263786B (enExample)
MX (1) MX387013B (enExample)
WO (1) WO2017220446A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610867D0 (en) 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation
GB201907647D0 (en) * 2019-05-30 2019-07-17 King S College London Therapeutic methods
CN111238897B (zh) * 2020-02-18 2023-03-28 上海市皮肤病医院 生物标本的处理方法与处理剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504014A (ja) 2001-06-08 2005-02-10 サイトビア インコーポレイテッド カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された３−アリール−５−アリール−［１，２，４］−オキサジアゾール類および類似体、並びにその使用法
JP2017537967A (ja) 2014-12-17 2017-12-21 キングス カレッジ ロンドン レチノイン酸受容体ベータ（ＲＡＲβ）アゴニストとしてのビシクロヘテロアリール−ヘテロアリール−安息香酸化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU710683B2 (en) 1995-06-07 1999-09-30 Nippon Shinyaku Co. Ltd. Pyrrole derivatives and medicinal composition
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
JP3995716B2 (ja) 1996-03-18 2007-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合環含有カルボン酸誘導体
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
GB9907461D0 (en) 1999-03-31 1999-05-26 King S College London Neurite regeneration
EP1025857A4 (en) 1997-10-22 2003-11-12 Eisai Co Ltd RETINOIC ACID AGONISTS, PREVENTIVE AND THERAPEUTIC AGENTS FOR NEPHRITES
JP2003081832A (ja) 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
WO2003062230A1 (en) 2002-01-21 2003-07-31 Eisai Co., Ltd. Conbinatorial library of heterocycle compounds
CN1894241A (zh) 2002-08-09 2007-01-10 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑
DK3549936T3 (da) 2003-04-11 2021-07-12 Ptc Therapeutics Inc 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense-undertrykkelse og behandlingen af sygdom
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
EP2402323A3 (en) 2004-10-13 2012-05-30 PTC Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
EP1907347A2 (en) 2005-07-12 2008-04-09 Arcadia Pharmaceuticals Inc. Compounds with activity at retinoic acid receptors
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
JP2011523997A (ja) 2008-05-30 2011-08-25 フォスター ホイーラー エナージア オサケ ユキチュア 酸素燃焼によって動力を発生させるための方法及び装置
EP2314569A1 (en) * 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
WO2011072281A1 (en) 2009-12-11 2011-06-16 Ptc Therapeutics, Inc. Methods for treating methylmalonic acidemia
GB201610867D0 (en) 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504014A (ja) 2001-06-08 2005-02-10 サイトビア インコーポレイテッド カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された３−アリール−５−アリール−［１，２，４］−オキサジアゾール類および類似体、並びにその使用法
JP2017537967A (ja) 2014-12-17 2017-12-21 キングス カレッジ ロンドン レチノイン酸受容体ベータ（ＲＡＲβ）アゴニストとしてのビシクロヘテロアリール−ヘテロアリール−安息香酸化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J Med Chem，Vol.43，2000年，p.2929-2937
平山令明，有機化合物結晶作製ハンドブック，2008年，p.17-23,37-40,45-51,57-65

Also Published As

Publication number Publication date
WO2017220446A1 (en) 2017-12-28
CA3025858C (en) 2023-09-26
US20210230151A1 (en) 2021-07-29
MX387013B (es) 2025-03-19
CN109415356B (zh) 2022-03-08
US11584741B2 (en) 2023-02-21
AU2017279865A1 (en) 2019-01-03
EP3475274A1 (en) 2019-05-01
GB201610867D0 (en) 2016-08-03
MX2018016250A (es) 2019-08-29
AU2017279865B2 (en) 2020-11-26
IL263786B (en) 2022-05-01
CA3025858A1 (en) 2017-12-28
IL263786A (en) 2019-01-31
CN109415356A (zh) 2019-03-01
US20190345147A1 (en) 2019-11-14
US10870644B2 (en) 2020-12-22
JP2019522650A (ja) 2019-08-15

Similar Documents

Publication Publication Date Title
JP6804580B2 (ja) ホルミルペプチド受容体様１（ｆｐｒｌ−１）受容体モジュレーターとしてのｎ−尿素置換アミノ酸のアミド誘導体
TWI776886B (zh) Sestrin-gator2交互作用之調節劑及其用途
JP6653253B2 (ja) ホルミルペプチド受容体モジュレーターとしてのｎ−尿素置換アミノ酸の誘導体
TW201329050A (zh) Ｔｒｐｖ１拮抗劑
AU2021200919A1 (en) MCT4 inhibitors for treating disease
JP6596090B2 (ja) レチノイン酸受容体ベータ（ＲＡＲβ）アゴニストとしてのビシクロヘテロアリール−ヘテロアリール−安息香酸化合物
US11584741B2 (en) Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation
US12006321B2 (en) Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists
CN102066345B (zh) *唑烷衍生物作为nmda拮抗剂
WO2015042071A1 (en) Diphenyl urea derivatives as formyl peptide receptor modulators
KR20050106421A (ko) 카르복실산 화합물
JP2001501221A (ja) Ｎｍｄａ（ｎ―メチル―ｄ―アスパラギン酸）アンタゴニスト
JP7488521B2 (ja) 急性脳損傷の治療のための化合物
WO2016179645A1 (en) 4h-pyran compounds as insulin-regulated aminopeptidase (irap) inhibitors
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
AU2020281943B2 (en) Substituted 4-(5-(benzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid compounds for use in therapy for neuropathic pain
JP7068277B2 (ja) Ｅａａｔ３阻害剤としてのイミダゾール化合物

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200601

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220607

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220706

R150 Certificate of patent or registration of utility model

Ref document number: 7102354

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250